Ptc Therapeutics, Inc.
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
Granted 32.0K · Sold 25.0K
Granted 103.6K · Sold 47.7K
Granted 123.0K · Sold 121.6K
Granted 141.4K · Sold 138.6K
Granted 20.0K · Sold 5.1K
Granted 18.8K · Sold 16.2K
Granted 32.9K · Sold 25.8K
Granted 238.7K · Sold 283.1K
Granted 16.0K · Sold 12.0K
Granted 16.0K · Sold 12.0K
Granted 4.0K
Granted 4.0K
Granted 42.0K · Sold 38.0K
Granted 4.0K
Granted 71.2K · Sold 75.7K
Granted 19.2K · Sold 21.5K
Granted 7.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schmertzler MichaelDirector · 7 transactions | — | 1.52M | 32.0K | — | 25.0K |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER, Director · 16 transactions | +16.6% | 394.0K | 103.6K | — | 47.7K |
| Boulding Mark ElliottEXEC. VP AND CLO · 83 transactions | +0.4% | 107.1K | 123.0K | — | 121.6K |
| Pauwels EricCHIEF BUSINESS OFFICER · 53 transactions | +19.3% | 91.0K | 141.4K | — | 138.6K |
| Gravier PierreCHIEF FINANCIAL OFFICER · 3 transactions | +21.4% | 87.3K | 20.0K | — | 5.1K |
| Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · 7 transactions | +4.1% | 79.1K | 18.8K | — | 16.2K |
| Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · 7 transactions | +12.2% | 70.2K | 32.9K | — | 25.8K |
| Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · 75 transactions | -40.8% | 62.9K | 238.7K | — | 283.1K |
| Southwell David PDirector · 3 transactions | +21.6% | 22.5K | 16.0K | — | 12.0K |
| Steele Glenn Jr MD PHDDirector · 3 transactions | +21.6% | 22.5K | 16.0K | — | 12.0K |
| Zeldis Jerome BDirector · 1 transaction | +21.6% | 22.5K | 4.0K | — | — |
| Smith Mary L.Director · 1 transaction | +22.5% | 21.8K | 4.0K | — | — |
| Jacobson Allan StevenDirector · 17 transactions | +22.9% | 21.5K | 42.0K | — | 38.0K |
| Young AlethiaDirector · 1 transaction | +23.4% | 21.1K | 4.0K | — | — |
| Reeve EmmaDirector · 30 transactions | -29.8% | 10.7K | 71.2K | — | 75.7K |
| Okey StephanieDirector · 7 transactions | -9.8% | 8.0K | 19.2K | — | 21.5K |
| Chutter Jessica CarolineDirector · 2 transactions | — | 7.3K | 7.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -822.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.